DJO Announces New Stemless Shoulder Offering – the AltiVate® Anatomic CS EDGE™ – New System Design Provides a More Bone-Baring Solution That Is Less Invasive Than Traditional Shoulder Stem Offerings

September 30, 2020

DJO today announced the launch of the canal-sparing AltiVate® Anatomic CS EDGE™ Shoulder System.

DJO notes the new system is designed to provide a more bone-sparing solution that is less invasive than traditional shoulder stem offerings.

DJO notes around 67,000 anatomic total shoulder arthroplasty procedures are done each year in the United States, and that number is expected to grow by 8.6% over the next two years.1 Through the introduction of newer tissue-sparing technologies like short stem and stemless shoulder implants, future growth in the US shoulder arthroplasty market is expected to be driven by increasing penetration into the younger patient population.2

“Our goal is to continue to drive innovation and bring market-leading products to patients; the addition of AltiVate Anatomic CS EDGE delivers the next advancement in our shoulder solutions portfolio,” said Louis Vogt, Vice President of Sales and Marketing, DJO Surgical®. “With the growing active patient population, the CS EDGE offers a unique bone-conserving solution to surgeons to address the needs of their anatomic arthroplasty patients.”

The design of the AltiVate Anatomic CS EDGE is based off a humeral fit analysis that was conducted to help optimize fit of peripherally targeted fins within the humeral metaphysis.3 The AltiVate Anatomic CS EDGE features a canal-sparing, 3-fin humeral stem with unique serrated fin tips, allowing surgeons the option to use the implant to cut into the bone. The system also incorporates P2™, a proprietary titanium porous coating that aids in the apposition of bone for excellent in-growth performance and an enhanced press-fit implantation.4

“As the first surgeon to use the AltiVate Anatomic CS EDGE, I was impressed by the press-fit implantation offered by this system. During insertion, you can feel the exceptional primary fixation and stability the implant design offers, which is critical in stemless applications,” said Dr. T. Bradley Edwards, Fondren Orthopedic Group in Houston, TX. “The innovative design of the CS EDGE system provides the best stemless implant fixation available in today’s market. In addition, the streamlined instrumentation creates efficiency, resulting in shorter operative time compared to other traditional stem systems I’ve used.”

Compatible with the AltiVate Anatomic e+™ glenoid component featuring patented Drop-and-Go® technology for immediate fixation,5 the CS EDGE™ Shoulder System gives surgeons the cutting edge needed in anatomic total shoulder arthroplasty solutions.

“I’ve been using the AltiVate Anatomic System for years, and I’m excited about the addition of the stemless product offering. The system maintains the intuitive and easy-to-use qualities that are characteristic of the AltiVate Anatomic brand,” said Dr. Jonathan Levy, Holy Cross Orthopedic Institute in Ft. Lauderdale, FL. “The immediate fixation achieved by the CS EDGE’s novel fin design and P2™ porous coating is quite remarkable, allowing me to confidently use the implant in patients of all ages. The CS EDGE has helped me to precisely replicate anatomy, minimize bone and blood loss during surgery, and facilitate shoulder arthroplasty in the outpatient setting with an efficient surgical workflow.”

The AltiVate® Anatomic CS EDGE™ is an important addition to DJO’s industry-leading AltiVate® Extremity Solutions product portfolio.


References

1 Smart TRAK® – Anatomic Total Shoulder Replacement Procedures, 2019

2 Smart TRAK® Shoulder Replacement https://app.smarttrak.com/markets/qs/d5ba9c8c85ec851cac1002a5f5bc1f81

3,4,5 Data on file at DJO®. Laboratory testing does not necessarily indicate clinical performance.

Dr. T. Bradley Edwards and Dr. Jonathan Levy are paid consultants for DJO®.

SourceDJO

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version